| Title | Consultation response to the National Institute for Health and Clinical Excellence on 'Proposed Remit for Single Technology Appraisal: Rituximab for the treatment of refractory rheumatoid arthritis [twinned with similar consultation on abatacept for refractory rheumatoid arthritis]' |